16 results about "Viral procapsid" patented technology

The present invention relates to the technical field of prevention and control of aquatic animal diseases, and specifically relates to a nanocomposite for a nervous necrosis virus, a preparation method therefor, and the use thereof. Provided in the present invention is a nanocomposite consisting of poly(lactic-co-glycolic acid), polyethyleneimine and a siRNA. Also provided in the present invention are a preparation method for the nanocomposite and the use thereof in the preparation of a drug for improving the survival rate of fish eggs infected with a nervous necrosis virus. The present invention constructs a vector for a capsid protein of the nervous necrosis virus by means of simulating the nervous necrosis virus and expresses same in cells, and screens out a siRNA that can effectively inhibit the expression of the viral capsid protein, thus constructing the nanocomposite for the nervous necrosis virus. The nanocomposite can block NNVs at the embryonic phase (fertilized eggs), thereby improving the survival rate of fish fry, and further opening up new possibilities for the treatment of early stage diseases in fish fry. The method is innovative in the field of artificial breeding of aquatic animals and provides new ideas for virus prevention and control in the field of aquaculture.

This application provides a novel differentiation factor for direct cross-differentiation from somatic cells to motor neurons, a composition containing the differentiation factor, a method for direct cross-differentiation using the composition, and uses for the novel differentiation factor. [Solution] A composition for direct cross-differentiation from somatic cells to induced motor neurons, the composition comprising (A) the Gsta4 protein or nucleic acid coding therefor; and (B) one or more proteins selected from Ascl1, Brn2, Myt1L, Hb9, ISL1, Lhx3, Ngn2 and NeuroD1 or nucleic acid coding therefor; and further comprising a viral capsid for transmitting (A) or (B).

Provided herein are compositions and methods of utilizing engineered viral capsid for therapeutic delivery. Also provided herein are methods of using the provided compositions and methods for delivering therapeutic for treating diseases.

Provided herein are targeting peptides and vectors containing a sequence that encodes the targeting peptides that deliver agents to specific substructures in the brain. Specifically, the targeting peptide is a component of a modified, sequence-specified adeno-associated virus (AAV) capsid protein further wherein the brain substructure may be the globus pallidus, putamen, internal capsule, caudate, claustrum, substantial nigra, motor cortex, insula,.temporal cortex, thalamus, hippocampus, subiculum, and deep cerebellar nuclei.

Provided are a modified adeno-associated virus capsid protein and the use thereof. The capsid protein comprises a substitution of about 5-8 amino acids as compared with a wild-type AAV capsid protein, and an AAV comprising the mutated capsid protein has increased infectivity to target tissue or target cells (such as heart or cardiomyocytes) than an AAV comprising the unmutated wild-type AAV capsid protein.

This invention relates to novel neurotropic adeno-associated virus (AAV) capsid variants. In particular, the invention relates to novel AAV capsid variants that efficiently transduce cells in the central nervous system (CNS) upon systemic administration, while exhibiting reduced transduction to peripheral organs. The invention further relates to a method for identifying AAV capsid variants having one or more desired properties, such as a combination of CNS targeting and peripheral organ detargeting.

This invention relates to modified adeno-associated virus (AAV) capsid proteins and their uses, wherein the capsid protein comprises about 5-8 amino acid substitutions relative to the wild-type AAV capsid protein, and AAV containing the modified capsid protein has increased infectivity to target tissues or target cells (e.g., heart or cardiomyocytes) compared to AAV containing the unmutated wild-type AAV capsid protein.

Disclosed herein is an oral fish vaccine comprising a recombinant cell comprising virus-like particles, wherein the recombinant cell is intact, inactivated, and does not exhibit antibiotic resistance. In one preferred embodiment, the inactivation is performed using sodium hypochlorite. In another preferred embodiment, the recombinant cell is Escherichia coli (E. coli) or Lactococcus lactis (L lactis). In a further preferred embodiment, the virus-like particles comprise nervous necrosis virus capsid proteins and the vaccine is used in treating or preventing viral nervous necrosis.

The application provides a purification method of foot-and-mouth disease virus capsid protein virus-like particles, and the purification method comprises the following steps: a fusion protein containing P1-2A is subjected to enzymolysis by 3C and TEV proteases to obtain an enzymolysis liquid; the enzymolysis liquid is subjected to nickel column purification by a nickel column to obtain foot-and-mouth disease virus capsid protein virus-like particle 5S protomers; and then foot-and-mouth disease virus capsid protein virus-like particles VLPs can be obtained by self-assembly. The purity of the foot-and-mouth disease virus capsid protein virus-like particles obtained by the purification method of the application is more than 90%, and the yield is more than 95%.

Virus-Like Particles derived from the subfamilies, Parahepevirinae and Orthohepevirinae, particularly those of the species Paslahepevirus balayani, which can cause acute hepatitis in humans and several mammalian species, and chronic conditions in immunocompromised patients are disclosed. Compositions of VirusLike Particles comprising viral capsid proteins capable of assembly in cultured cells that may be purified, disassembled, and reassembled in the presence of other molecules suitable for use as therapeutic drug products to facilitate the targeting and delivery of cargo molecules to specific cells or tissues, or as antigenic agents designed to stimulate responses to heterologous epitopes exposed on the surfaces of Virus- Like Particles are provided. Functional capsids comprising polypeptide sequences comprising amino acid substitutions, insertions, or deletions of amino acid encoded by a consensus of ORF2 genes, that are functionally-similar or have enhanced properties compared to capsid polypeptides encoded by naturally-occurring viruses obtained from clinical samples or prototype Hepatitis E Viruses (HEV) are provided.

This invention belongs to the field of veterinary biological agent technology, specifically relating to a bacterial-enzyme complex preparation for the prevention and treatment of transmissible gastroenteritis (TGEV) in pigs, its preparation method, and its application. The bacterial-enzyme complex preparation comprises microcapsule particles; the core material of each microcapsule particle includes a complex of probiotics and a synergistic enzyme system; the complex of probiotics includes *Lactobacillus rhamnosus*, *Bacillus coagulans*, *Pediococcus pentosus*, and *Kluyveromyces marsupialis*. In the bacterial-enzyme complex preparation for the prevention and treatment of TGEV provided by this invention, the complex probiotics and the synergistic enzyme system form a synergistic effect. Lactic acid secreted by *Lactobacillus rhamnosus* can lower the intestinal pH, disrupting the TGEV survival environment; antimicrobial peptides produced by *Bacillus coagulans* can directly cleave the viral capsid protein; lysozyme can degrade viral envelope polysaccharides; and neutral protease, β-glucanase, and xylanase can destroy the viral adsorption sites on the intestinal mucosa. This quadruple action significantly enhances the antiviral effect.

Provided herein are adeno-associated virus (AAV) particles comprising viral capsid proteins that preferentially transduce retinal cells. A modified AAV capsid protein disclosed herein comprises a framework protein and a peptide that is inserted into the framework protein. Also provided are nucleic acids encoding said modified AAV capsid protein. Also provided are methods of using the AAV particles, for example, for enhancing expression in retinal cells and for treating retinal disease.

This invention discloses a method for preparing and applying drug-loaded silk protein formulations that cross the blood-brain barrier, relating to the field of biomedical materials technology. To optimize the performance of nanodelivery systems by utilizing silk protein fibers to regulate the self-assembly of bioactive particles and enhance their application value in the treatment of various diseases such as Alzheimer's, the invention specifically includes silk protein nanofibers, functional therapeutic active components, and mannose / rabies virus capsid protein. The silk protein nanofibers self-assemble to form nanoparticles, and the functional therapeutic active components utilize the self-assembly process of the silk protein nanofibers to prepare bioactive silk protein nanocarriers. This invention features a simple and convenient process. The resulting stable drug-loaded silk protein nanodelivery carrier formulation achieves high brain penetration efficiency by binding to different receptors on brain microvascular endothelial cells, providing a novel approach for the design of silk protein nanodelivery carriers.

The present disclosure relates generally to adeno-associated virus (AAV) capsid polypeptides and encoding nucleic acid molecules. The disclosure also relates to AAV vectors comprising the capsid polypeptides, and nucleic acid vectors (e.g. plasmids) comprising the encoding nucleic acids molecules, as well as to host cells comprising the vectors. The disclosure also relates to methods and uses of the polypeptides, encoding nucleic acids molecules, vectors and host cells.